R01 CA118919/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2006	1
2007	2
2008	2
2009	3
2010	5
2011	5
2012	2
2014	3
2015	5
2016	4
2017	1
2018	3
2019	1
2020	3
2021	0

1

Macropinocytosis Exploitation by Cancers and Cancer Therapeutics.

Ha KD, Bidlingmaier SM, Liu B. Ha KD, et al. Front Physiol. 2016 Sep 12;7:381. doi: 10.3389/fphys.2016.00381. eCollection 2016. Front Physiol. 2016. PMID: 27672367 Free PMC article. Review.

2

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.

Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. Clin Cancer Res. 2020 Nov 15;26(22):6028-6038. doi: 10.1158/1078-0432.CCR-20-0400. Epub 2020 Sep 11. Clin Cancer Res. 2020. PMID: 32917735

3

Methods for site-specific drug conjugation to antibodies.

Behrens CR, Liu B. Behrens CR, et al. MAbs. 2014 Jan-Feb;6(1):46-53. doi: 10.4161/mabs.26632. MAbs. 2014. PMID: 24135651 Free PMC article. Review.

4

Manipulation of Cell-Type Selective Antibody Internalization by a Guide-Effector Bispecific Design.

Lee NK, Su Y, Bidlingmaier S, Liu B. Lee NK, et al. Mol Cancer Ther. 2019 Jun;18(6):1092-1103. doi: 10.1158/1535-7163.MCT-18-1313. Epub 2019 Apr 8. Mol Cancer Ther. 2019. PMID: 30962321 Free PMC article.

5

The development of potential antibody-based therapies for myeloma.

Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG 3rd, Liu B. Sherbenou DW, et al. Blood Rev. 2015 Mar;29(2):81-91. doi: 10.1016/j.blre.2014.09.011. Epub 2014 Sep 28. Blood Rev. 2015. PMID: 25294123 Free PMC article. Review.

6

ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen.

Su Y, Zhang X, Bidlingmaier S, Behrens CR, Lee NK, Liu B. Su Y, et al. Cancer Res. 2020 Oct 15;80(20):4552-4564. doi: 10.1158/0008-5472.CAN-20-1418. Epub 2020 Aug 31. Cancer Res. 2020. PMID: 32868383

7

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.

Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Su Y, et al. JCI Insight. 2018 Sep 6;3(17):e121497. doi: 10.1172/jci.insight.121497. eCollection 2018 Sep 6. JCI Insight. 2018. PMID: 30185663 Free PMC article.

8

Quantitative ^99mTc Labeling Kit for HYNIC-Conjugated Single Chain Antibody Fragments Targeting Malignant Mesothelioma.

He J, Feng J, Su Y, Seo Y, Liu B. He J, et al. Bioconjug Chem. 2020 Jul 15;31(7):1750-1755. doi: 10.1021/acs.bioconjchem.0c00319. Epub 2020 Jul 6. Bioconjug Chem. 2020. PMID: 32628464

9

Identification of Posttranslational Modification-Dependent Protein Interactions Using Yeast Surface Displayed Human Proteome Libraries.

Bidlingmaier S, Liu B. Bidlingmaier S, et al. Methods Mol Biol. 2015;1319:193-202. doi: 10.1007/978-1-4939-2748-7_10. Methods Mol Biol. 2015. PMID: 26060076 Free PMC article. Review.

10

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells.

Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Sherbenou DW, et al. J Clin Invest. 2016 Dec 1;126(12):4640-4653. doi: 10.1172/JCI85856. Epub 2016 Nov 14. J Clin Invest. 2016. PMID: 27841764 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results